Celldex Net Working Capital from 2010 to 2024

CLDX Stock  USD 27.44  0.38  1.37%   
Celldex Therapeutics Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital will likely drop to about 241.4 M in 2024. During the period from 2010 to 2024, Celldex Therapeutics Net Working Capital regression line of annual values had r-squared of  0.46 and arithmetic mean of  173,112,410. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
400.6 M
Current Value
241.4 M
Quarterly Volatility
109.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 5.8 M or Selling General Administrative of 29.4 M, as well as many indicators such as Price To Sales Ratio of 293, Dividend Yield of 0.0 or PTB Ratio of 3.62. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Celldex Therapeutics Correlation against competitors.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Latest Celldex Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Celldex Therapeutics over the last few years. It is Celldex Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Celldex Net Working Capital Regression Statistics

Arithmetic Mean173,112,410
Geometric Mean147,792,224
Coefficient Of Variation63.26
Mean Deviation87,124,281
Median117,020,000
Standard Deviation109,518,709
Sample Variance11994.3T
Range345.5M
R-Value0.68
Mean Square Error7010.5T
R-Squared0.46
Significance0.01
Slope16,559,897
Total Sum of Squares167920.9T

Celldex Net Working Capital History

2024241.4 M
2023400.6 M
2022299.1 M
2021394.3 M
2020183.6 M
201955.1 M
201886.5 M

About Celldex Therapeutics Financial Statements

Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital400.6 M241.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.